Effects of a 1-year calcium-enriched permeate supplement on bone health in postmenopausal females: The RENEW randomized controlled intervention trial.

What Was Tested

This randomized controlled trial looks at Copper (Supplement).

Linear mixed-effects models were used to assess fixed and random effects. adjusted for multiple outcomes.

Why It Was Studied

Calcium-enriched permeate (CP) and inulin may enhance absorption and bone mineral density (BMD).

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Copper (Supplement).

A placebo (an inactive look-alike) gave the Copper (Supplement) group a baseline to be compared against.

Primary outcome was C-terminal telopeptides of type I collagen; secondary outcomes were procollagen type I N-terminal propeptide and BMD.

What Was Measured

The subject headings attached to it are Bone Density, Dietary Supplements, Calcium, Dietary, Postmenopause, Osteoporosis, Postmenopausal, Biomarkers and Collagen Type I.

The authors tagged it with the keywords CTX, PINP, antiresorptive effect, bone mineral density, bone turnover biomarkers and iPTH.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (The American journal of clinical nutrition), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.